We are proud to announce the official arrival of DOLOSPASMYL and DOLOCOLMYL in pharmacies since the 27th of November 2025 !

With these new launches, Mayoly is further strengthening its support for patients suffering from sensitive intestines.

Widely prescribed for the symptomatic treatment of functional intestinal disorders, particularly bloating, with METEOSPASMYL®, Mayoly is taking a new step forward in conquering the OTC market with DOLOSPASMYL®. DOLOSPASMYL is a non-reimbursable, over-the-counter medicine available in two pack sizes: 10 soft capsules, allowing new patients to try DOLOSPASMYL, and 30 capsules, meeting the needs of our loyal patients.

To further support patients, Mayoly is also expanding its range with DOLOCOLMYL®, a medical device designed to relieve the symptoms of irritable bowel syndrome: abdominal pain, bloating and transit disorders.

These two launches confirm Mayoly’s ambition to strengthen its expertise, visibility and growth in the field of gastroenterology.

Your comments 1

  • Congratulations french team for the launch, big first step into OTC with Dolospamsyl and range extension with local innovation Dolocolmyl!

1sur3

Leave a Reply